Summary:
The primary objective for this study is to compare the clinical efficacy of weekly abatacept in combination with standard treatment to standard treatment alone.
The study design includes a 24 week double blind, randomized, placebo controlled trial period, followed by a 28 week open-label treatment period during which all subjects will receive abatacept.
Qualified Participants Must:
• Men and Women(not nursing or pregnant)
•
18+ years old
•
Diagnosis of Definite or Probable IIM
Qualified Participants May Receive:
Participants meeting all of the Inclusion/Exclusion criteria will be compensated $60 per visit